Study of β-catenin, E-cadherin and vimentin in oral squamous cell carcinoma with and without lymph node metastases

Diagnostic Pathology

Rajni Yadav¹  Alok Thakar²  Amit Kumar Dinda¹  Manoj Kumar Singh¹  Partheeban Balasundaram¹ 

[1] Department of Pathology, All India Institute of Medical Sciences, New Delhi, India;Department of Otorhinolaryngology and Head & Neck Surgery, All India Institute of Medical Sciences, New Delhi, India

关键词: E-cadherin;    Vimentin;    β-catenin;    Lymph node;    Metastases;    Squamous cell carcinoma;   

Others  :  1150119
DOI  :  10.1186/1746-1596-9-145

 received in 2014-01-11, accepted in 2014-02-09,  发布年份 2014

【 摘 要 】

Background

Despite great improvement in the surgical treatment and adjunctive therapy for oral squamous cell carcinoma (OSCC), prognosis remains dismal in advanced cases. Regional metastatic disease is known to reduce recurrence free survival and disease specific survival significantly. The present study was conducted to evaluate the role of cell adhesion molecules β-catenin, E-cadherin and vimentin in predicting tumour metastasis of OSCC.

Methods

A total of sixty cases of oral squamous cell carcinoma were included for the study which comprised of 30 cases with lymph node metastases and 30 cases without metastases. Immunohistochemistry was performed for β-catenin, E-cadherin and vimentin on both the test groups along with 30 controls from normal buccal mucosa and inflammatory lesions each.

Results

There was no significant difference between the immunoreactivity for β-catenin, E-cadherin and vimentin between OSCC with and without lymph node metastases. Vimentin immunopositivity was noted with varying intensity in all cases of OSCC.

Conclusions

E-cadherin and β-catenin are probably not the key determinants for regional metastases in OSCC. The role of vimentin expression in OSCC and metastases is controversial and needs to be studied further.

【 授权许可】

   
2014 Balasundaram et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, Molinari R: Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg 1985, 8:67-73.
• [3]Fillies T, Buerger H, Gaertner C, August C, Brandt B, Joos U, Werkmeister R: Catenin expression in T1/2 carcinomas of the floor of the mouth. Int J Oral Maxillofac Surg 2005, 34:907-911.
• [4]Ramaekers FCS, Haeg D, Kant A, Moesker O, Jap PH, Vooijs GP: Coexpression of keratin and vimentin type intermediate filaments in human metastatic carcinoma cells. Proc Nactl Acad Sci USA 1983, 80:2618-2623.
• [5]Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP: Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 1989, 109:1495-1509.
• [6]Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP: Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 1989, 49:4258-4263.
• [7]Iyer PV, Leong ASY: Poorly differentiated squamous cell carcinomas of the skin can express vimentin. J Cutan Pathol 1992, 19:34-39.
• [8]Imai K, Kumagal S, Nakagawa K, Yamamoto E, Nakanishi I, Okada Y: Immunolocalization of desmoglein and intermediate filaments in human oral squamous cell carcinomas. Head Neck 1995, 17:204-212.
• [9]Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, Ogawa M: Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996, 73:1233-1236.
• [10]Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovacs AF, Stauber RH: Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007, 211:532-540.
• [11]Oda T, Kanai K, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W, Sugimura T, Hirohashi S: E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 1994, 91:1858-1862.
• [12]Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Lihara K, Doki Y, Hirano S, Takeichi M, Mori T: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991, 139:17-23.
• [13]Matsui S, Shiozaki H, Inoue M, Tamura S, Doki Y, Kadowaki T, Iwazawa T, Shimaya K, Nagafuchi A, Tsukita S: Immunohistochemical evaluation of α-catenin expression in human gastric cancer. Virchows Arch 1994, 424:375-381.
• [14]Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M: Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992, 118:703-714.
• [15]Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB: Upregulation of vimentin and aberrant expression of E-cadherin/β catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010, 23:213-224.
• [16]Kurtz KA, Hoffman HT, Zimmerman MB, Robinson RA: Decreased E-Cadherin but not beta-catenin expression is associated with vascular invasion and decreased survival in head and neck squamous carcinomas. Otolaryngol Head Neck Surg 2006, 134:142-146.
• [17]Gurkiran K, Sunitha C, Nirmala R, Laxmi R: Expression of E-cadherin in primary oral squamous cell carcinoma and metastatic lymph nodes: An immunohistochemical study. Indian J Dent Res 2009, 20:71-76.
• [18]Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C: Aberrant β-catenin expression in the histologic differentiation of oral squamous cell carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci 2010, 52:633-640.
• [19]Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial mesenchymal transition: new insights in signaling, development and disease. J Cell Biol 2006, 172:973-981.
• [20]Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I: Snail-dependent and –independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem 2006, 54:1263-1275.
• [21]de Araujo VC, Pinto DS Jr, de Sousa SOM, Nunes FD, de Araujo NS: Vimentin in oral squamous cell carcinoma. Eur Arch Otorhinolaryngol 1993, 250:105-109.
• [22]Islam S, Kim JB, Trendel J, Wheelock MJ, Johnson KR: Vimentin expression in human squamous carcinoma cells: relationship with phenotypic changes and cadherin-based cell adhesion. J Cell Biochem 2000, 78:141-150.
• [23]Tanaka N, Odajima T, Ogi K, Ikeda T, Satoh M: Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 2003, 89:557-563.
• [24]Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A: Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol 2006, 42:190-200.
• [25]Cruz MC, Pereira AL, Lopes FF, Nonaka CF, Silva RR, Freitas Rde A, Souza LB, Pinto LP: Immunohistochemical expression of E-cadherin and CD44v6 in squamous cell carcinomas of the lower Lip and tongue. Braz Dent J 2009, 20:64-69.
• [26]Andrews NA, Jones AK, Helliwell TR, Kinsella AR: Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 1997, 75:1474-1480.
• [27]Wang X, Zhang J, Fan M: The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RTPCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:547-554.
• [28]Rodrigo JP, Dominguez F, Alvarez C: Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 2002, 38:1059-1064.
• [29]Takes RP, de Jong RJ B, Schuuring E, Hermans J, Vis AA, Litvinov SV, van Kreiken JH: Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997, 123:412-419.
• [30]Bukholm IK, Nesland JN, Karesen R, Jacobsen U, Borresen-Dale AL: E-cadherin and alpha, beta and gamma catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998, 185:262-266.
• [31]Kinsella AR, Green B, Lepts GC, Hill CL, Bowie G, Taylor BA: The role of the cell adhesion molecule E-cad in large bowel tumour cell invasion and metastasis. Br J Cancer 1993, 67:904-909.
• [32]Bankfalvi A, Krabort M, Vegh A, Felszeghy E, Piffko J: Deranged expression of the E-cadherin/b-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 2002, 31:450-457.
• [33]Cai ZG, Shi XJ, Gao Y, Wei MJ, Wang CY, Yu GY: β-catenin expression pattern in primary oral squamous cell carcinoma. Chin Med J 2008, 121:1866-1870.
• [34]Murakami A, Nakagawa T, Fukushima C, Torii M, Sueoka K, Nawata S, Takeda O, Ishikawa M, Sugino N: Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. Oncol Rep 2008, 19:99-104.
• [35]Freitas Rde A, Silveira EJ, Silveira JP, Silva FM, Amorim RF: Correlation of ß-catenin expresssion and metastasis in tongue squamous cell carcinoma. Acta Cir Bras 2010, 25:513-517.
• [36]Chow V, Yuen AP, Lam KY, Tsao GS, Ho WK, Wei WI: A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 2001, 127:59-63.
• [37]Yamada K, Jordan R, Mori M, Speight PM: The relationship between E-cadherin expression, clinical stage and tumour differentiation in oral squamous cell carcinoma. Oral Dis 1997, 3:82-85.
• [38]Williams HK, Sanders DSA, Jankowski JAZ, Landini G, Brown AM: Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med 1998, 27:308-317.
• [39]Okamoto M, Nishimine M, Kishi M, Kirita T, Sugimura M, Nakamura M, Konishi N: Prediction of delayed neck metastasis in patients with stage I/II squamous cell carcinoma of the tongue. J Oral Pathol Med 2002, 31:227-233.
• [40]Jiang Q, Yang H, Cheng C, Xiong H, Liu S, Long J, Zhang Y, Fang W, Liu Z: Decreased P27 protein expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Diagnostic Pathol 2013, 8:212. BioMed Central Full Text
• [41]Li Y, Guo H, Dong D, Wu H, Li E: Expression and prognostic relevance of Cyclophilin A and matrix metalloproteinase 9 in esophageal squamous cell carcinoma. Diagnostic Pathol 2013, 8:207. BioMed Central Full Text
• [42]Peng J, Hu Q, Liu W, He X, Cui L, Chen X, Yang M, Liu H, Wei W, Liu S, Wang H: USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagnostic Pathol 2013, 8:177. BioMed Central Full Text
• [43]Wang T, Mi Y, Pian L, Gao P, Xu H, Zheng Y, Xuan X: RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells. Diagnostic Pathol 2013, 8:104. BioMed Central Full Text
• [44]Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagnostic Pathol 2012, 7:180. BioMed Central Full Text
• [45]Fletcher AM, Heaford AC, Trask DK: Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue specific Mir-205. Transl Oncol 2008, 1(4):202-208.
• [46]Nikitakis NG, Rivera H, Lopes MA, Siavash H, Reynolds MA, Ord RA, Sauk JJ: Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am J Clin Pathol 2003, 119(4):574-586.